Biomarkers /
BCR
Back to Biomarkers List
Overview
Breakpoint cluster region (BCR) is a gene that functions as a fusion partner with ABL1 to encode a fusion protein that is a result of the reciprocal translocation between chromosomes 22 and 9. The translocation produces the Philadelphia chromosome - a hallmark feature of chronic myelogenous leukemia (CML). Fusions, rearrangements, missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as hematopoietic and lymphoid cancers, intestinal cancer, and skin cancer.
Biomarker-Directed Therapies
BCR is a predictive biomarker for use of dasatinib, bosutinib, nilotinib, imatinib, and ponatinib in patients.
Chronic myeloid leukemia and acute lymphoblastic leukemia have the most therapies with BCR as a predictive biomarker.
Of the therapies with BCR as a predictive biomarker, 4 are FDA-approved in at least one clinical setting and 5 have NCCN guidelines in at least one clinical setting.
BCR-ABL1 Fusion is the top alteration on BCR targeted by therapies [4].
Bosutinib +
Acute Lymphoblastic Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
Chronic Myeloid Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
Dasatinib +
Acute Lymphoblastic Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (FDA, NCCN), Relapse (NCCN), Treatment Induction (NCCN) | |
| Note: Not recommended as a single agent for patients 40 years and older with Ph-positive ALL. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (NCCN), Refractory (NCCN), Relapse (NCCN) | |
| Note: Resistance to prior TKI-containing therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Refractory (NCCN) |
Chronic Myeloid Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (MCG), Relapse (FDA), Treatment Induction (FDA, NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
Imatinib +
Acute Lymphoblastic Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (FDA), Relapse (FDA) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Refractory (NCCN) |
Chronic Myeloid Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Treatment Induction (FDA, NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Refractory (NCCN) |
Nilotinib +
Acute Lymphoblastic Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) | |
| Note: Resistance to prior TKI-containing therapy. |
Chronic Myeloid Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (FDA), Treatment Induction (FDA, NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (FDA, NCCN), Relapse (NCCN) | |
| Note: Resistance or intolerant to prior therapy that included imatinib. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) | |
| Note: Applies if the cancer is resistant or intolerant to prior therapy that included imatinib. |
Ponatinib +
Acute Lymphoblastic Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA, NCCN), Refractory (FDA, NCCN), Relapse (FDA, NCCN), Treatment Induction (FDA, NCCN) | |
| Note: Indicated for T315I-positive Ph+ ALL. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA, NCCN), Refractory (FDA, NCCN), Relapse (FDA, NCCN), Treatment Induction (FDA, NCCN) | |
| Note: Indicated for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated. |
Chronic Myeloid Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (FDA, NCCN), Relapse (FDA, NCCN) | |
| Note: Indicated for T315I-positive CML (chronic phase, accelerated phase, or blast phase). |
Clinical Trials
BCR status serves as an inclusion eligibility criteria in 241 clinical trials, of which 155 are open and 86 are closed. Of the trials that contain BCR status as an inclusion criterion, 2 are early phase 1 (1 open), 54 are phase 1 (25 open), 35 are phase 1/phase 2 (22 open), 108 are phase 2 (79 open), 4 are phase 2/phase 3 (3 open), 26 are phase 3 (18 open), 7 are phase 4 (5 open), and 5 are no phase specified (2 open).
The most frequent alteration to serve as an inclusion eligibility criterion is BCR-ABL1 Fusion [4].
Significance of BCR in Diseases
Chronic Myeloid Leukemia +
BCR is an inclusion criterion in 115 clinical trials for chronic myeloid leukemia, of which 74 are open and 41 are closed. Of the trials that contain BCR status and chronic myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 24 are phase 1 (11 open), 19 are phase 1/phase 2 (12 open), 52 are phase 2 (40 open), 11 are phase 3 (7 open), 5 are phase 4 (3 open), and 3 are no phase specified (1 open) [4].
Dasatinib, nilotinib, bosutinib, imatinib, and ponatinib have evidence of efficacy in patients with BCR mutation in chronic myeloid leukemia [4].
Acute Lymphoblastic Leukemia +
BCR is an inclusion criterion in 92 clinical trials for acute lymphoblastic leukemia, of which 59 are open and 33 are closed. Of the trials that contain BCR status and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 23 are phase 1 (11 open), 10 are phase 1/phase 2 (8 open), 43 are phase 2 (28 open), 2 are phase 2/phase 3 (2 open), 7 are phase 3 (6 open), 2 are phase 4 (2 open), and 3 are no phase specified (1 open) [4].
Ponatinib, bosutinib, dasatinib, imatinib, and nilotinib have evidence of efficacy in patients with BCR mutation in acute lymphoblastic leukemia [4].
Acute Myeloid Leukemia +
BCR is an inclusion criterion in 117 clinical trials for acute myeloid leukemia, of which 67 are open and 50 are closed. Of the trials that contain BCR status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 32 are phase 1 (15 open), 21 are phase 1/phase 2 (15 open), 48 are phase 2 (29 open), 3 are phase 2/phase 3 (2 open), 9 are phase 3 (5 open), and 2 are no phase specified (0 open) [4].
Myelodysplastic Syndromes +
BCR is an inclusion criterion in 75 clinical trials for myelodysplastic syndromes, of which 44 are open and 31 are closed. Of the trials that contain BCR status and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 24 are phase 1 (11 open), 12 are phase 1/phase 2 (10 open), 31 are phase 2 (19 open), 2 are phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 2 are no phase specified (0 open) [4].
Hodgkin Lymphoma +
BCR is an inclusion criterion in 23 clinical trials for hodgkin lymphoma, of which 12 are open and 11 are closed. Of the trials that contain BCR status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 10 are phase 2 (6 open), and 1 is no phase specified (0 open) [4].
Multiple Myeloma +
BCR is an inclusion criterion in 20 clinical trials for multiple myeloma, of which 13 are open and 7 are closed. Of the trials that contain BCR status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), 8 are phase 2 (5 open), and 1 is no phase specified (0 open) [4].
Non-Hodgkin Lymphoma +
BCR is an inclusion criterion in 19 clinical trials for non-hodgkin lymphoma, of which 11 are open and 8 are closed. Of the trials that contain BCR status and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 9 are phase 2 (6 open) [4].
B-Cell Acute Lymphoblastic Leukemia +
BCR is an inclusion criterion in 18 clinical trials for B-cell acute lymphoblastic leukemia, of which 15 are open and 3 are closed. Of the trials that contain BCR status and B-cell acute lymphoblastic leukemia as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 7 are phase 2 (5 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [4].
Acute Biphenotypic Leukemia +
BCR is an inclusion criterion in 17 clinical trials for acute biphenotypic leukemia, of which 8 are open and 9 are closed. Of the trials that contain BCR status and acute biphenotypic leukemia as inclusion criteria, 7 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), 7 are phase 2 (3 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [4].
Chronic Myelomonocytic Leukemia +
BCR is an inclusion criterion in 16 clinical trials for chronic myelomonocytic leukemia, of which 11 are open and 5 are closed. Of the trials that contain BCR status and chronic myelomonocytic leukemia as inclusion criteria, 6 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), 6 are phase 2 (5 open), and 1 is no phase specified (0 open) [4].
Chronic Lymphocytic Leukemia +
BCR is an inclusion criterion in 15 clinical trials for chronic lymphocytic leukemia, of which 9 are open and 6 are closed. Of the trials that contain BCR status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 5 are phase 1/phase 2 (3 open), and 4 are phase 2 (4 open) [4].
Acute Leukemia +
BCR is an inclusion criterion in 11 clinical trials for acute leukemia, of which 4 are open and 7 are closed. Of the trials that contain BCR status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [4].
Mantle Cell Lymphoma +
BCR is an inclusion criterion in 11 clinical trials for mantle cell lymphoma, of which 5 are open and 6 are closed. Of the trials that contain BCR status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].
Burkitt Lymphoma +
BCR is an inclusion criterion in 10 clinical trials for Burkitt lymphoma, of which 4 are open and 6 are closed. Of the trials that contain BCR status and Burkitt lymphoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [4].
Anaplastic Large Cell Lymphoma +
BCR is an inclusion criterion in 9 clinical trials for anaplastic large cell lymphoma, of which 4 are open and 5 are closed. Of the trials that contain BCR status and anaplastic large cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].
Myeloproliferative Neoplasm +
BCR is an inclusion criterion in 9 clinical trials for myeloproliferative neoplasm, of which 5 are open and 4 are closed. Of the trials that contain BCR status and myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [4].
Follicular Lymphoma +
BCR is an inclusion criterion in 8 clinical trials for follicular lymphoma, of which 3 are open and 5 are closed. Of the trials that contain BCR status and follicular lymphoma as inclusion criteria, 3 are phase 1 (2 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].
Juvenile Myelomonocytic Leukemia +
BCR is an inclusion criterion in 8 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 5 are closed. Of the trials that contain BCR status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [4].
Marginal Zone Lymphoma +
BCR is an inclusion criterion in 8 clinical trials for marginal zone lymphoma, of which 3 are open and 5 are closed. Of the trials that contain BCR status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].
Lymphoblastic Lymphoma +
BCR is an inclusion criterion in 7 clinical trials for lymphoblastic lymphoma, of which 5 are open and 2 are closed. Of the trials that contain BCR status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [4].
Lymphoma +
BCR is an inclusion criterion in 7 clinical trials for lymphoma, of which 3 are open and 4 are closed. Of the trials that contain BCR status and lymphoma as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (0 open), 2 are phase 2 (2 open), and 2 are phase 3 (1 open) [4].
Myelofibrosis +
BCR is an inclusion criterion in 7 clinical trials for myelofibrosis, of which 3 are open and 4 are closed. Of the trials that contain BCR status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (1 open), and 3 are phase 2 (2 open) [4].
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma +
BCR is an inclusion criterion in 6 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 4 are closed. Of the trials that contain BCR status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].
Diffuse Large B-Cell Lymphoma +
BCR is an inclusion criterion in 6 clinical trials for diffuse large B-cell lymphoma, of which 4 are open and 2 are closed. Of the trials that contain BCR status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), and 1 is phase 1/phase 2 (1 open) [4].
Mixed Phenotype Acute Leukemia +
BCR is an inclusion criterion in 6 clinical trials for mixed phenotype acute leukemia, of which 5 are open and 1 is closed. Of the trials that contain BCR status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [4].
Prolymphocytic Leukemia +
BCR is an inclusion criterion in 6 clinical trials for prolymphocytic leukemia, of which 3 are open and 3 are closed. Of the trials that contain BCR status and prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [4].
Refractory Anemia With Excess Blasts +
BCR is an inclusion criterion in 6 clinical trials for refractory anemia with excess blasts, of which 2 are open and 4 are closed. Of the trials that contain BCR status and refractory anemia with excess blasts as inclusion criteria, 2 are phase 1 (0 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [4].
Secondary Acute Myeloid Leukemia +
BCR is an inclusion criterion in 6 clinical trials for secondary acute myeloid leukemia, of which 6 are open and 0 are closed. Of the trials that contain BCR status and secondary acute myeloid leukemia as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
T-Cell Acute Lymphoblastic Leukemia +
BCR is an inclusion criterion in 6 clinical trials for T-cell acute lymphoblastic leukemia, of which 5 are open and 1 is closed. Of the trials that contain BCR status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [4].
Lymphoplasmacytic Lymphoma +
BCR is an inclusion criterion in 5 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 4 are closed. Of the trials that contain BCR status and lymphoplasmacytic lymphoma as inclusion criteria, 4 are phase 2 (1 open) and 1 is no phase specified (0 open) [4].
Myelodysplastic/Myeloproliferative Neoplasm +
BCR is an inclusion criterion in 5 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 4 are open and 1 is closed. Of the trials that contain BCR status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [4].
Small Lymphocytic Lymphoma +
BCR is an inclusion criterion in 5 clinical trials for small lymphocytic lymphoma, of which 2 are open and 3 are closed. Of the trials that contain BCR status and small lymphocytic lymphoma as inclusion criteria, 4 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome +
BCR is an inclusion criterion in 4 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain BCR status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [4].
Acute Undifferentiated Leukemia +
BCR is an inclusion criterion in 4 clinical trials for acute undifferentiated leukemia, of which 3 are open and 1 is closed. Of the trials that contain BCR status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [4].
B-Cell Non-Hodgkin Lymphoma +
BCR is an inclusion criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain BCR status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
Double-Hit Lymphoma +
BCR is an inclusion criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain BCR status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [4].
Refractory Anemia +
BCR is an inclusion criterion in 4 clinical trials for refractory anemia, of which 1 is open and 3 are closed. Of the trials that contain BCR status and refractory anemia as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].
Therapy-Related Myelodysplastic Syndrome +
BCR is an inclusion criterion in 4 clinical trials for therapy-related myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain BCR status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Malignant Solid Tumor +
BCR is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain BCR status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].
Myelodysplastic Syndrome With Excess Blasts-2 +
BCR is an inclusion criterion in 3 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 2 are closed. Of the trials that contain BCR status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 3 are phase 2 (1 open) [4].
Plasma Cell Leukemia +
BCR is an inclusion criterion in 3 clinical trials for plasma cell leukemia, of which 1 is open and 2 are closed. Of the trials that contain BCR status and plasma cell leukemia as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [4].
T-Cell Lymphoblastic Leukemia/Lymphoma +
BCR is an inclusion criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain BCR status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [4].
Therapy-Related Acute Myeloid Leukemia +
BCR is an inclusion criterion in 3 clinical trials for therapy-related acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain BCR status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].
Acute Erythroid Leukemia +
BCR is an inclusion criterion in 2 clinical trials for acute erythroid leukemia, of which 2 are open and 0 are closed. Of the trials that contain BCR status and acute erythroid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Acute Megakaryoblastic Leukemia +
BCR is an inclusion criterion in 2 clinical trials for acute megakaryoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain BCR status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Acute Promyelocytic Leukemia +
BCR is an inclusion criterion in 2 clinical trials for acute promyelocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain BCR status and acute promyelocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is no phase specified (0 open) [4].
Adult T-Cell Leukemia/Lymphoma +
BCR is an inclusion criterion in 2 clinical trials for adult T-cell leukemia/lymphoma, of which 0 are open and 2 are closed. Of the trials that contain BCR status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is phase 3 (0 open) and 1 is no phase specified (0 open) [4].
B-Cell Prolymphocytic Leukemia +
BCR is an inclusion criterion in 2 clinical trials for B-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain BCR status and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].
Burkitt Leukemia +
BCR is an inclusion criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain BCR status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [4].
Mature T-Cell And NK-Cell Lymphoma/Leukemia +
BCR is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain BCR status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [4].
Mature T-Cell And NK-Cell Neoplasm +
BCR is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain BCR status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].
Natural Killer Cell Lymphoblastic Leukemia/Lymphoma +
BCR is an inclusion criterion in 2 clinical trials for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 1 is closed. Of the trials that contain BCR status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 2 are phase 2 (1 open) [4].
Peripheral T-Cell Lymphoma +
BCR is an inclusion criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain BCR status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [4].
T-Cell Non-Hodgkin Lymphoma +
BCR is an inclusion criterion in 2 clinical trials for T-cell non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain BCR status and T-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (1 open) [4].
T-Cell Prolymphocytic Leukemia +
BCR is an inclusion criterion in 2 clinical trials for T-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain BCR status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].
Acute Bilineal Leukemia +
BCR is an inclusion criterion in 1 clinical trial for acute bilineal leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCR status and acute bilineal leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].
Acute Leukemia Of Ambiguous Lineage +
BCR is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains BCR status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [4].
Acute Myeloid Leukemia With Myelodysplasia-Related Changes +
BCR is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains BCR status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [4].
Adult Acute Lymphoblastic Leukemia +
BCR is an inclusion criterion in 1 clinical trial for adult acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCR status and adult acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].
Aplastic Anemia +
BCR is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains BCR status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].
B-Cell Lymphoblastic Leukemia/Lymphoma +
BCR is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic leukemia/lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCR status and B-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].
B-Cell Lymphoblastic Lymphoma +
BCR is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCR status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].
Desmoplastic Small Round Cell Tumor +
BCR is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains BCR status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [4].
Ewing Sarcoma +
BCR is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains BCR status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Histiocytic And Dendritic Cell Neoplasm +
BCR is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BCR status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Indolent Non-Hodgkin Lymphoma +
BCR is an inclusion criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCR status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Leukemia +
BCR is an inclusion criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCR status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].
Mature B-Cell Lymphoma/Leukemia +
BCR is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains BCR status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].
Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +
BCR is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BCR status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Mediastinal Large B-Cell Lymphoma +
BCR is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BCR status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Melanoma +
BCR is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains BCR status and melanoma as inclusion criteria, 1 is no phase specified (0 open) [4].
Mixed Phenotype Acute Leukemia, B/Myeloid, NOS +
BCR is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, B/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains BCR status and mixed phenotype acute leukemia, B/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].
Mixed Phenotype Acute Leukemia, T/Myeloid, NOS +
BCR is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains BCR status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].
Myelodysplastic Syndrome With Excess Blasts-1 +
BCR is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains BCR status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [4].
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +
BCR is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains BCR status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].
Myeloid Neoplasm +
BCR is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BCR status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Myeloid Sarcoma +
BCR is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BCR status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Neuroblastoma +
BCR is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains BCR status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Plasma Cell Neoplasm +
BCR is an inclusion criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains BCR status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].
Polycythemia Vera +
BCR is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains BCR status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [4].
Primary Myelofibrosis +
BCR is an inclusion criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains BCR status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Rhabdomyosarcoma +
BCR is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains BCR status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Secondary Myelodysplastic Syndrome +
BCR is an inclusion criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains BCR status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].
Small Lymphocytic Leukemia +
BCR is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains BCR status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].
Solid Neoplasm +
BCR is an inclusion criterion in 1 clinical trial for solid neoplasm, of which 0 are open and 1 is closed. Of the trial that contains BCR status and solid neoplasm as inclusion criteria, 1 is no phase specified (0 open) [4].
T-Cell Lymphoblastic Lymphoma +
BCR is an inclusion criterion in 1 clinical trial for T-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCR status and T-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].
T-Cell And NK-Cell Neoplasm +
BCR is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BCR status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Therapy-Related Chronic Myelomonocytic Leukemia +
BCR is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCR status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].
Therapy-Related Myeloid Neoplasm +
BCR is an inclusion criterion in 1 clinical trial for therapy-related myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BCR status and therapy-related myeloid neoplasm as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].
Waldenstrom Macroglobulinemia +
BCR is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains BCR status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 2 (1 open) [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
